U.S. researchers are set to conduct a groundbreaking clinical trial testing the use of gene-edited pig livers to treat individuals experiencing sudden liver failure. The trial, cleared by the Food and Drug Administration, aims to temporarily filter patients’ blood through the pig liver, allowing their own liver to rest and potentially heal. With an estimated 35,000 people hospitalized annually in the U.S. due to sudden liver failure and limited treatment options, this innovative approach could offer a new solution.
Partnering with OrganOx, pig producer eGenesis is spearheading this unique study, expected to commence later this spring. Rather than transplanting the pig liver, researchers will connect it externally to study participants. The hope is that by filtering the patient’s blood through the pig liver for several days, it may provide the liver with the opportunity to regenerate.
In prior experiments involving deceased bodies, the pig liver successfully supported certain functions of a human liver for a few days, showcasing its potential as a temporary bridge. The trial aims to enroll up to 20 intensive-care unit patients who are ineligible for a liver transplant. Utilizing a device developed by Britain’s OrganOx, which is currently used for preserving donated human livers, participants’ blood will be circulated through the pig liver.
This trial represents the latest advancement in utilizing gene-edited pig organs to address critical medical needs. In parallel efforts, pig kidneys from eGenesis and United Therapeutics have been utilized in experimental transplants.
